Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

PepVerse Revolutionising peptide-based drug discovery with high-throughput mimotope mapping

Coordinator
The Chancellor Masters and Scholars of the University of Cambridge, United Kingdom
Runs
1 June 2025 to 30 November 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101213674

What the project is doing

In the project's own words, from its summary on CORDIS.

Peptide-based drugs offer distinct advantages over existing molecular therapeutics, such as their ability to engage targets that have proven challenging for small molecules, and their capability to penetrate cells and modulate intracellular targets, which conventional biologics cannot achieve. However, despite this potential, the development of peptide-based medicines has lagged due to the lack of high-quality, large-scale protein-peptide interaction datasets essential for rational AI-driven peptide design.

During the ERC Consolidator Grant DiProPhys, we developed a platform that can profile protein/peptide interactions at scale. As part of the PepVerse project, we will leverage this platform to generate proof-of-concept data for commercial exploitation. Specifically, we will generate binding data for three high-value therapeutic targets that currently lack orally available drugs due to difficulties in identifying non-peptidomimetic small molecule binders.

These data will not only validate the platform’s ability to discover binders but will also provide specific starting points for high-value drug discovery programmes. Moreover, the data will showcase the platform’s potential to create the world’s largest protein/peptide mimotope dataset foundational for advancing any peptide-based drug discovery programme --- a goal we aim to achieve with the help of private capital. In addition to generating these validation data, which are key for fundraising and translating the technology to a commercial entity, our other critical objectives for the project include establishing solid IP protection for the technology and building relationships with key stakeholders, such as advanced library providers and pharma partners.

By the end of the project, we aim to have generated robust validation data, filed an intellectual property application, and raised funds to launch a peptide-based drug discovery company

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor Masters and Scholars of the University of CambridgeCambridgeUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI